U.S. Markets close in 4 hrs 25 mins

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

WATERTOWN, Mass.--(BUSINESS WIRE)--

Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will present at the following upcoming conferences:

Cowen & Company 39th Annual Health Care Conference
Date: Wednesday, March 13, 2019
Presentation Time: 10:40 a.m. ET
Speaker: Mark Iwicki, Chairman, President and Chief Executive Officer
Location: Boston, MA

Oppenheimer’s 29th Annual Healthcare Conference
Date: Wednesday, March 20, 2019
Presentation Time: 8:35 a.m. ET
Speaker: Todd Bazemore, Chief Operating Officer
Location: New York, NY

To access a live webcast and subsequent archived recording of each presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the United States Food and Drug Administration (FDA) and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005026/en/